In a recent Phase 1b clinical trial, MEI Pharma's drug candidate ME-344, when combined with bevacizumab, demonstrated positive results in treating patients with relapsed metastatic colorectal cancer (mCRC).

Processa Pharmaceuticals, a clinical-stage company, has introduced promising results from a Phase 1b study of its Next Generation Capecitabine (NGC-Cap) at the AACR Annual Meeting.

Enliven Therapeutics has reported encouraging early results from a Phase 1 clinical trial of ELVN-001, a novel small molecule kinase inhibitor targeting chronic myeloid leukemia (CML).

Lamassu Biotech has received approval from the FDA to commence Phase 1/2a clinical trials for its innovative cancer treatment, SA53-OS.

MEI Pharma's Board of Directors has made a strategic decision to focus on the clinical development of their drug candidates, voruciclib and ME-344, based on positive clinical data.

April 12, 2024 —Cbio A/S, a biopharmaceutical firm based in Copenhagen, has announced its financial results for 2023 and provided an update on the company's progress.

Agenus Inc. has reported new findings from its Phase 1 clinical study of BOT/BAL combination therapy for patients with metastatic colorectal cancer (CRC).

In a recent analysis of 7,200 cancer research abstracts from the American Association for Cancer Research's (AACR) annual gathering, several significant trends emerged.

April 15, 2024 —An innovative gene therapy named AVB-101 is currently under investigation to treat frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations.

April 15, 2024 —NiKang Therapeutics Inc. recently announced the commencement of a phase 1/1b clinical trial involving their novel drug candidate NKT3447.

April 15, 2024 —Neumora Therapeutics, a biopharmaceutical firm listed on Nasdaq as NMRA, has encountered a setback in its clinical trials.

April 15, 2024 —Walden Biosciences, a private clinical development company, has reported positive results from its Phase 1+ study of WAL0921.